What people report after using products sold as retatrutide

These are the themes that come up again and again in public discussion of products sold as retatrutide. For each one: what people describe, roughly how often it seems to appear, what the trials of the real drug found, and what a clinician would say. Read the caveat first, because it changes how every theme should be understood.

Nausea and vomiting

What people describe: feeling sick for a day or two after each injection, food aversions, sometimes vomiting. How common in reports: very common; probably the single most-discussed effect.

What the trials found: nausea in 28.6% to 42.4% of people on retatrutide in TRIUMPH-1 depending on dose, against 14.8% on placebo; vomiting in 10.6% to 25.3% against 4.8%. Most cases were mild to moderate and clustered around dose increases.^[2]

What a clinician would say: expected with the real drug, and consistent with the reports. Two things would concern them: vomiting that stops you keeping fluids down, and nausea with severe tummy pain, which could be pancreatitis. See nausea, vomiting and GI effects.

Fatigue and low energy

What people describe: tiredness, feeling flat, needing more sleep. How common: common.

What the trials found: fatigue was not among the most frequently reported effects in the topline releases.^[2]

What a clinician would say: eating far less than usual, drinking less because you feel sick, and losing weight fast will all make you tired, whatever the cause. Dehydration on its own causes fatigue, dizziness and headaches.^[3] Tiredness that is severe, or comes with jaundice, dark urine or bruising, is different and is covered under liver symptoms below.

"Food noise" going quiet

What people describe: the constant background thinking about food stops; they forget to eat. How common: very common, and usually reported as a positive.

What the trials found: the trials measured weight, not thoughts, but reduced appetite was a recorded effect: 19.0% and 18.2% on the two doses in TRIUMPH-4 against 9.4% on placebo.^[4]

What a clinician would say: this is the mechanism working, and it is exactly what the licensed drugs in the class do too. The concern is the other side of it: people who forget to eat can end up short of protein, fluid and micronutrients. See eating when appetite is low.

Heart rate and palpitations

What people describe: a higher resting heart rate on a fitness tracker, awareness of the heartbeat, occasional fluttering. How common: common.

What the trials found: a dose-dependent rise in heart rate in Phase 2, peaking around week 24 and easing by weeks 36 to 48. Arrhythmias were reported in 2% to 11% across retatrutide arms against 2% on placebo, mostly mild to moderate, with one severe prolonged-QT event in a participant also taking ondansetron.^[5] The Phase 3 topline releases did not give heart-rate figures.^[2]

What a clinician would say: a modest rise in heart rate is expected with the real drug. A pounding, racing or irregular heartbeat, fainting or chest pain is not something to watch and wait on, and an ECG is a simple test. See heart rate and rhythm.

"Reta rash", tingling and skin sensitivity

What people describe: tingling, burning, pins and needles, skin that feels sensitive to touch or clothing, sometimes described as a rash even when nothing is visible. How common: common, and often a surprise because it does not happen with Wegovy or Mounjaro.

What the trials found: this is dysesthesia, a new finding in the Phase 3 programme: 5.1% to 12.5% in TRIUMPH-1 and 8.8% to 20.9% in TRIUMPH-4, against under 1% on placebo, generally mild and rarely a reason to stop.^[2][4]

What a clinician would say: the reports match a genuine effect of the drug, which is unusual among these themes. A visible, spreading, painful or hot rash is a different thing and could be an infection or an allergic reaction. The dysesthesia page covers what is known.

Hair shedding

What people describe: more hair in the brush or plughole, usually a few months in. How common: common.

What the trials found: hair loss is not in the retatrutide topline releases, but the licensed relative Wegovy lists hair loss as a common side effect in its UK product information, at 2.5% against 1.0% on placebo, mostly mild and usually recovering during treatment.^[6]

What a clinician would say: rapid weight loss of any kind can trigger telogen effluvium, a temporary shedding that starts a few months after the trigger and grows back. The NHS lists weight loss among the causes of temporary hair loss.^[7] Low protein and iron make it worse. It is not a sign that a product is fake or genuine; the misinformation tracker covers that claim.

Constipation

What people describe: going days without a bowel movement, bloating. How common: common, though discussed less than nausea.

What the trials found: constipation in 23.8% to 26.1% in TRIUMPH-1 against 10.9% on placebo.^[2]

What a clinician would say: expected, manageable with fluids, fibre and movement, and worth mentioning to a pharmacist if it lasts.^[8] Constipation with severe pain, vomiting or a swollen, hard tummy needs urgent assessment.

Mood changes and low mood

What people describe: irritability, flatness, loss of pleasure in food and sometimes in other things. How common: occasional, but discussed seriously when it comes up.

What the trials found: the topline releases did not report mood outcomes.^[2]

What a clinician would say: poor sleep, under-eating, dehydration and rapid change can all lower mood, and it is not possible to separate those from any drug effect in a community report. Low mood that lasts more than a couple of weeks, or any thoughts of self-harm, should go to a GP regardless of the cause. NHS 111 and the Samaritans (116 123) are there at any hour.

Injection-site reactions

What people describe: redness, itching or a small lump where the injection went in. How common: common.

What the trials found: injection-site reactions are listed as a common effect for licensed injectables in this class.^[9]

What a clinician would say: mild redness for a day is expected with any injection. Spreading redness, heat, increasing pain, pus or fever is an infection, and with an unlicensed product made outside any sterile process, that is a real risk. See injectables and infection.

"It did nothing"

What people describe: no appetite change, no side effects, no weight loss, sometimes after weeks. How common: occasional, but notable because it is not what the trials would predict.

What the trials found: in TRIUMPH-1 even the lowest dose produced 17.6% average weight loss over 80 weeks, and the great majority of participants responded.^[2]

What a clinician would say: the simplest explanation is that the product did not contain what the label said. Testing in 2026 found around 30% of products sold as retatrutide under-strength and one with none of the drug at all.^[1] "It did nothing" is a product-quality report, not a drug report.

"It hit far harder than expected"

What people describe: overwhelming nausea, vomiting or diarrhoea from the first use, out of proportion to what others describe. How common: occasional.

What the trials found: side effects rose with dose in every trial.^[2]

What a clinician would say: this is what an over-strength product looks like. A vial labelled 10 mg tested at about 19 mg, and a gastroenterologist described a patient losing around eight litres of fluid a day to diarrhoea who needed hospital fluids.^[10] Severe diarrhoea can cause dangerous dehydration and kidney injury.^[3] Anyone in this situation needs NHS 111 or A&E, not reassurance.

Liver symptoms

What people describe: unusual tiredness, tummy pain, itching, dark urine, yellowing of the eyes. How common: rare in reports, but the most serious theme on this page.

What the trials found: transient liver-enzyme rises in about 1% of participants, with no pattern of serious liver injury.^[5]

What a clinician would say: the Australian cluster of at least six acute liver injuries in people using products labelled retatrutide, with further cases reported since, suggests contaminants rather than the drug, and one woman came close to needing a transplant after two uses.^[11][12] Any of these symptoms after using an unlicensed product needs same-day medical attention and a liver blood test. See the liver-injury cluster and liver and kidney.